Fintel reports that on September 19, 2024, UBS initiated coverage of Exelixis (NasdaqGS:EXEL) with a Neutral recommendation.
Analyst Price Forecast Suggests 4.25% Upside
As of August 26, 2024, the average one-year price target for Exelixis is $27.97/share. The forecasts range from a low of $18.18 to a high of $34.65. The average price target represents an increase of 4.25% from its latest reported closing price of $26.83 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exelixis is 2,076MM, an increase of 3.08%. The projected annual non-GAAP EPS is 1.31.
What is the Fund Sentiment?
There are 960 funds or institutions reporting positions in Exelixis. This is an decrease of 3 owner(s) or 0.31% in the last quarter. Average portfolio weight of all funds dedicated to EXEL is 0.32%, an increase of 3.18%. Total shares owned by institutions decreased in the last three months by 0.94% to 275,392K shares. 
The put/call ratio of EXEL is 1.55, indicating a bearish outlook.
What are Other Shareholders Doing?
Farallon Capital Management holds 27,102K shares representing 9.50% ownership of the company. In its prior filing, the firm reported owning 26,678K shares , representing an increase of 1.56%. The firm increased its portfolio allocation in EXEL by 0.10% over the last quarter.
Renaissance Technologies holds 15,163K shares representing 5.32% ownership of the company. In its prior filing, the firm reported owning 15,102K shares , representing an increase of 0.40%. The firm increased its portfolio allocation in EXEL by 2.60% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 9,061K shares representing 3.18% ownership of the company. In its prior filing, the firm reported owning 9,439K shares , representing a decrease of 4.18%. The firm decreased its portfolio allocation in EXEL by 6.96% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 8,845K shares representing 3.10% ownership of the company. In its prior filing, the firm reported owning 9,148K shares , representing a decrease of 3.42%. The firm decreased its portfolio allocation in EXEL by 10.97% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 6,962K shares representing 2.44% ownership of the company. In its prior filing, the firm reported owning 7,345K shares , representing a decrease of 5.51%. The firm decreased its portfolio allocation in EXEL by 5.86% over the last quarter.
Exelixis Background Information
(This description is provided by the company.)
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
